Evidence on the effectiveness of policies promoting price transparency - A systematic review

Joosse, Iris R.; Tordrup, David; Glanville, Julie; Kotas, Eleanor; Mantel‐Teeuwisse, Aukje K.; Ham, Hendrika A. van den

doi:10.1016/j.healthpol.2022.11.002

Cited by 7 publications

(2 citation statements)

References 21 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the sample of responses received, information about the price or the P&R arrangement used to fund a therapy tended to be confidential in nature. While a degree of confidentiality can facilitate negotiation ( Joosse et al, 2022 ), ethically there is a case for enabling reporting of clinical evidence that is accrued using public money under the access schemes ( Dal-Ré, 2015 ; Guerra-Júnior et al, 2017 ). The World Health Assembly Resolution 72.8 calls for more transparency across a number of areas including prices in other countries, costs of research and patent expiry ( Perehudoff, 2022 ).…”

Section: Discussionmentioning

confidence: 99%

Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries

Rejon-Parrilla,

Espin,

Garner

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Introduction: Advanced Therapy Medicinal Products are a type of therapies that, in some cases, hold great potential for patients without an effective current therapeutic approach but they also present multiple challenges to payers. While there are many theoretical papers on pricing and reimbursement (P&R) options, original empirical research is very scarce. This paper aims to provide a comprehensive international review of regulatory and P&R decisions taken for all ATMPs with centralized European marketing authorization in March 2022.Methods: A survey was distributed in July 2022 to representatives of 46 countries.Results: Responses were received from 20 countries out of 46 (43.5%). 14 countries reimbursed at least one ATMP. Six countries in this survey reimbursed no ATMPs.Conclusion: Access to ATMPs is uneven across the countries included in this study. This arises from regulatory differences, commercial decisions by marketing authorization holders, and the divergent assessment processes and criteria applied by payers. Moving towards greater equality of access will require cooperation between countries and stakeholders, for example, through the WHO Regional Office for Europe’s Access to Novel Medicines Platform.

show abstract

Section: Discussionmentioning

confidence: 99%

Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries

Rejon-Parrilla,

Espin,

Garner

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Transparency in pricing, research and development costs, and licensing agreements can enhance accountability and access. It allows stakeholders to understand the factors influencing drug pricing and access [ 30 ].…”

Section: Reviewmentioning

confidence: 99%

India’s Decision to Deny an Extension of Patent for Bedaquiline: A Public Health Imperative

Yadav,

Rawal,

Jeyaraman

2023

Cureus

View full text Add to dashboard Cite

Tuberculosis (TB) remains a major global public health concern, which has become worse in low- and middle-income nations due to the rise of drug-resistant strains of the disease. Bedaquiline, a groundbreaking anti-TB drug, shows great promise for addressing multidrug-resistant TB (MDR-TB). However, the recent decision by India to reject the application for a patent extension on bedaquiline raises crucial questions regarding access to essential medicines and public health requirements. This article examines the significance of India's rejection of the patent extension for bedaquiline, outlining the global implications of this decision and its impact on intellectual property rights, access to medicines, and the future of drug development. India's stance serves as a model for other countries to prioritize public health in their patent-related decisions, underlining the need for a balanced approach to intellectual property rights, innovation, and affordability in the pharmaceutical sector. In the context of the ongoing battle against drug-resistant TB, India's decision on bedaquiline signifies the evolving landscape of pharmaceutical patent practices in the service of global public health.

show abstract

A conceptual framework to build effective medicine pricing policies for low and middle-income countries (LMICs)

Babar

2024

Research in Social and Administrative Pharmacy

View full text Add to dashboard Cite

Evidence on the effectiveness of policies promoting price transparency - A systematic review

Cited by 7 publications

References 21 publications

Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries

Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries

India’s Decision to Deny an Extension of Patent for Bedaquiline: A Public Health Imperative

A conceptual framework to build effective medicine pricing policies for low and middle-income countries (LMICs)

Contact Info

Product

Resources

About